(Q38005958)

26 August 2017

Androgen receptor directed therapies in castration-resistant metastatic prostate cancer (English)

1 reference

26 August 2017

1 reference

Won Kim

1

1 reference

PubMed ID

22539224

26 August 2017

Charles J Ryan

series ordinal

2

1 reference

26 August 2017

1 June 2012

1 reference

Current Treatment Options in Oncology

26 August 2017

1 reference

26 August 2017

13

1 reference

26 August 2017

2

1 reference

26 August 2017

189-200

1 reference

https://scigraph.springernature.com/pub.10.1007/s11864-012-0188-2

26 August 2017

0 references

cites work

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

C17,20-lyase inhibitors I. Structure-based de novo design and SAR study of C17,20-lyase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-012-0188-2

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

21 January 2018

1 reference

12 December 2020

Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment

1 reference

12 December 2020

Importance of continued testicular suppression in hormone-refractory prostate cancer

1 reference

12 December 2020

Ketoconazole Blocks Testosterone Synthesis

1 reference

12 December 2020

Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal

1 reference

12 December 2020

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

10.1007/S11864-012-0188-2

Identifiers

DOI

1 reference

PubMed ID

22539224

Dimensions Publication ID

26 August 2017

0 references

1 reference

PubMed ID

22539224